Our results therefore suggest that screening cancer patient EVs for the presence of MEK1 could be a useful form of “personalized medicine” to select patient populations who most likely would respond to MEK inhibitors without the deleterious effects caused by inhibiting MEK1 activity in EVs. The gene discussed is MAP2K7; the disease is cancer.